U.S. patent number 8,468,901 [Application Number 12/449,603] was granted by the patent office on 2013-06-25 for controlled transfer biological sample collection devices and methods of using such devices.
This patent grant is currently assigned to GE Healthcare Bio-Sciences Corp.. The grantee listed for this patent is Michael A. Harvey, Elizabeth A. Moran, Breck O. Parker, John Pipinias, Stevan Paul Tortorella. Invention is credited to Michael A. Harvey, Elizabeth A. Moran, Breck O. Parker, John Pipinias, Stevan Paul Tortorella.
United States Patent |
8,468,901 |
Harvey , et al. |
June 25, 2013 |
Controlled transfer biological sample collection devices and
methods of using such devices
Abstract
The field of the present invention pertains to a controlled
transfer biological collection device using a dry solid storage and
transfer medium and a method for the collection of biological
material of interest (genetic or proteinaceous material) in a form
suitable for storage and/or subsequent analysis. Specifically, the
present invention provides for a sampling device that controls the
transfer of the biological sample to the storage medium by holding
the storage medium and a moveable sample collection cmember having
an analyte collection surface. The invention further provides for a
method not only for storing a biological analyte on this collection
device but also for analyzing the stored biological analyte using
methods that are suited for automated analyzing systems.
Inventors: |
Harvey; Michael A. (Spofford,
NH), Parker; Breck O. (Saco, ME), Tortorella; Stevan
Paul (Wells, ME), Moran; Elizabeth A. (Randolph, NJ),
Pipinias; John (Elliot, ME) |
Applicant: |
Name |
City |
State |
Country |
Type |
Harvey; Michael A.
Parker; Breck O.
Tortorella; Stevan Paul
Moran; Elizabeth A.
Pipinias; John |
Spofford
Saco
Wells
Randolph
Elliot |
NH
ME
ME
NJ
ME |
US
US
US
US
US |
|
|
Assignee: |
GE Healthcare Bio-Sciences
Corp. (Piscataway, NJ)
|
Family
ID: |
39326733 |
Appl.
No.: |
12/449,603 |
Filed: |
February 15, 2008 |
PCT
Filed: |
February 15, 2008 |
PCT No.: |
PCT/GB2008/000542 |
371(c)(1),(2),(4) Date: |
August 14, 2009 |
PCT
Pub. No.: |
WO2008/099196 |
PCT
Pub. Date: |
August 21, 2008 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20100106057 A1 |
Apr 29, 2010 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
11707313 |
Feb 16, 2007 |
7748283 |
|
|
|
Current U.S.
Class: |
73/864.91 |
Current CPC
Class: |
G01N
1/02 (20130101); B01L 3/505 (20130101); B01L
3/5023 (20130101); G01N 2035/00356 (20130101); G01N
2001/028 (20130101); B01L 2300/069 (20130101); B01L
2200/027 (20130101) |
Current International
Class: |
B01L
3/00 (20060101) |
Field of
Search: |
;73/864.91,864.51
;422/561,547,69 ;436/175-180 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
2005221615 |
|
Sep 2005 |
|
AU |
|
1950149 |
|
Apr 2007 |
|
CN |
|
0057542 |
|
Aug 1982 |
|
EP |
|
0064392 |
|
Nov 1982 |
|
EP |
|
WO-90/13819 |
|
Nov 1990 |
|
WO |
|
WO-03/050507 |
|
Jun 2003 |
|
WO |
|
WO-2005/087376 |
|
Sep 2005 |
|
WO |
|
WO-2006/042004 |
|
Apr 2006 |
|
WO |
|
Primary Examiner: Macchiarolo; Peter J.
Assistant Examiner: Bellamy; Tamiko
Parent Case Text
CROSS-REFERENCES TO RELATED APPLICATIONS
The present application is a 35 U.S.C. .sctn.371 national stage of
PCT application PCT/GB2008/000542, filed Feb. 15, 2008, which is a
continuation-in-part application of U.S. Ser. No. 11/707,313, filed
Feb. 16, 2007, the disclosures of all of which are incorporated
herein by reference.
Claims
We claim:
1. A collection device for a biological sample that contains
degradable biologically sourced analytes comprising: a) a moveable
sample collection member having an analyte collection surface; b) a
storage medium comprising at least one stabilizing reagent that
preserves at least one biological sample analyte for transport or
storage; c) a storage medium holder having a means for holding the
storage medium in a fixed position; and d) a means for holding the
moveable sample collection member comprising a resilient member
attached to the storage medium holder; wherein the means for
holding the moveable sample collection allows the moveable
collection member surface to move between a first open position for
collecting the biological sample on the analyte collection surface
and a second closed position facing or contacting at least a
portion of the storage medium.
2. The device of claim 1, wherein the storage medium and the
analyte collection surface are held together for traceability
purposes.
3. The device of claim 1 wherein the means for holding the moveable
sample collection member comprises a unitary connection between the
storage medium holder and the moveable sample collection
member.
4. A method for collecting a biological sample that contains
degradable biologically sourced analytes comprising: a) obtaining a
device comprised of i) a moveable sample collection member having
an analyte collection surface; ii) a storage medium comprising at
least one stabilizing reagent that preserves at least one
biological sample analyte for transport or storage; iii) a storage
medium holder having a means for holding the storage medium in a
fixed position; and iv) a means for holding the moveable sample
collection member; wherein the means for holding the moveable
sample collection member allows the moveable collection member
surface to move between a first open position for collecting the
biological sample on the analyte collection surface and a second
closed position facing or contacting at least a portion of the
storage medium; b) moving the moveable collection member surface to
the first open position; c) first contacting the moveable
collection member surface with the biological sample; and d)
subsequently contacting the moveable collection member surface with
the storage medium.
5. The method of claim 4 wherein the storage medium is removed from
the storage medium holder after the moveable collection member
surface is contacted with the storage medium.
6. The method of claim 4 wherein the stabilizing reagent comprises
a weak base and a chelating agent.
7. The method of claim 4 wherein the stabilizing reagent comprises
a chaotropic salt.
8. The method of claim 4 wherein the degradable biologically
sourced analytes include nucleic acids, proteins, and respective
fragments thereof.
9. The method of claim 4 wherein the biological sample is selected
from the group consisting of saliva, blood, serum, lymph fluids,
buccal cells, mucosal cells, cerebrospinal fluid, semen, vaginal
fluid, feces, plasma, urine, a suspension of cells, or a suspension
of cells and viruses.
10. The method of claim 4 wherein the storage medium holder
releaseably holds the storage medium in the fixed position,
allowing the storage medium to be separated from the storage
medium.
11. The method of claim 4 wherein the analyte collection surface is
absorbent.
12. The method of claim 4 wherein the device also comprises an
identification label.
13. The method of claim 4 wherein the storage medium holder is
dimensioned and configured to expose at least a portion of the
storage medium for removal of the storage medium from the storage
medium holder.
14. The method of claim 4 also comprising a sterility envelope
surrounding the other device elements and those other elements are
sterile and free from any biological sample analytes.
15. The method of claim 4 also comprising the step of manipulating
the storage medium so as to remove at least a portion of the
biologically sourced analyte present on the storage medium after
the step of subsequently contacting the moveable collection member
surface with the storage medium.
16. A kit comprising a device as defined in claim 1 and one or more
components selected from the group consisting of purification
reagents for subsequent analysis of the sample, buffers, storage
systems and containers.
17. A method for collecting a buccal sample for analysis for
purposes of population genetics, pharmacogenomics studies or
personal genetic archiving, the method comprising: a) providing the
device as defined in claim 1; b) moving the moveable collection
member surface to the first open position; c) first contacting the
moveable collection member surface with a buccal sample; d)
subsequently contacting the moveable collection member surface with
the storage medium; and e) analyzing the buccal sample.
18. The device of claim 1 wherein the stabilizing reagent comprises
a weak base and a chelating agent.
19. The device of claim 18 wherein the stabilizing reagent further
comprises uric acid or a urate salt.
20. The device of claim 1 wherein the stabilizing reagent comprises
a chaotropic salt.
21. The device of claim 1 wherein the degradable biologically
sourced analytes include nucleic acids, proteins, and respective
fragments thereof.
22. The device of claim 1 wherein the biological sample is selected
from the group consisting of saliva, blood, serum, lymph fluids,
buccal cells, mucosal cells, cerebrospinal fluid, semen, vaginal
fluid, feces, plasma, urine, a suspension of cells, or a suspension
of cells and viruses.
23. The device of claim 1 wherein the storage medium holder
releaseably holds the storage medium in the fixed position,
allowing the storage medium to be separated from the storage
medium.
24. The device of claim 1 wherein the analyte collection surface is
absorbent.
25. The device of claim 1 wherein the device also comprises an
identification label.
26. The device of claim 1 wherein the storage medium holder is
dimensioned and configured to expose at least a portion of the
storage medium for removal of the storage medium from the storage
medium holder.
27. The device of claim 1 also comprising a sterility envelope
surrounding the other device elements and those other elements are
sterile and free from any biological sample analytes.
28. The method of claim 4 wherein subsequent to step c) and prior
to step d), the method further comprises moving the moveable
collection member surface from the first open position to the
second closed position.
29. The method of claim 6 wherein the stabilizing reagent further
comprises uric acid or a urate salt.
30. A collection device for a biological sample that contains
degradable biologically sourced analytes comprising: a) a moveable
sample collection member having an analyte collection surface; b) a
storage medium comprising at least one stabilizing reagent that
preserves at least one biological sample analyte for transport or
storage; and c) a storage medium holder having a means for holding
the storage medium in a fixed position and a means for holding the
moveable sample collection member; wherein the means for holding
the moveable sample collection member comprises a resilient member
attached to the storage medium holder; and wherein the moveable
sample collection holding means allows the moveable collection
member surface to move between a first open position for collecting
the biological sample on the analyte collection surface and a
second closed position facing or contacting at least a portion of
the storage medium.
Description
BACKGROUND OF THE INVENTION
(1) Field of the Invention
The field of the present invention pertains to a controlled
transfer biological collection device using a dry solid storage and
transfer medium and a method for the collection of biological
material of interest (genetic or proteinaceous material) in a form
suitable for storage and/or subsequent analysis. Specifically, the
present invention provides for a sampling device that controls the
transfer of the biological sample to the storage medium by holding
the storage medium and a moveable sample collection member having
an analyte collection surface. The invention further provides for a
method not only for storing a biological analyte on this collection
device but also for analyzing the stored biological analyte using
methods that are suited for automated analyzing systems.
(2) Description of the Related Art, Including Information Disclosed
Under 37 CFR 1.97 & 1.98
The collection of biological samples (such as blood) and extracting
DNA for genetic analysis from the sample has been widely used by
the forensics and medical community for identification purposes,
for paternity testing, for genetic diagnostic testing in new born
screening programs, for genetic typing for predisposition to
disease and for genetic characterization for drug susceptibility.
However, due to the invasive nature of blood collection,
alternative non-invasive methods are coming into favor. Current
methods involve scraping cellular mucosa from inside the oral
cavity using any of a number of different devices such as
cytobrushes, cotton or Dacron swabs, mouthwash swish and rinse
methods, foam tipped swabs, and supported cellulosic filter paper
collection techniques (known as the Bode method). These methods
require time-consuming, labor intensive extraction methods.
The introduction of treated storage matrices into the forensics
community has significantly streamlined the collection and
extraction of DNA from a variety of samples. The use of FTA.RTM.
brand treated matrices (from Whatman, Inc. of Florham Park, N.J.
USA) with non-invasive buccal cell collection techniques presents a
new set of problems. With the use of conventional buccal swabs, one
can fail to transfer buccal cells to the treated matrix in a
consistent and reproducible manner. If the swab used to collect the
sample is separate and distinct from the treated matrix receiving
the sample, then forensic traceability issues arise, particularly
if the two become separated later in the chain of custody of
forensic evidence.
Examples of treated matrices for biological sample collection or
storage and associated collection devices can be found in the
following US patents: U.S. Pat. NOS. 6,627,226, 6,447,804,
6,294,203, 6,168,922, 5,976,572, 5,972,386, 5,939,259, and U.S.
Pat. No. 5,756,126. Basically, these patents use two different
methodologies for stabilizing biological samples.
The first stabilizing method uses a combination of an absorbent
material as a storage medium that does not bind to nucleic acids
and a chaotropic salt impregnated about the storage medium. (For
the purposes of the cited prior art and the present invention,
"chaotropic salts" include any substance capable of altering the
secondary, tertiary, or quaternary structure of biomolecules in
aqueous solution, but leaves the primary structure intact.)
Preferably, a chaotropic salt is said to inactivate any nucleic
acid amplification inhibitors present in the biological source, by
precipitation, by inducing the inhibitor to irreversibly bind to
the matrix, or by causing substantially irreversible denaturation
of the inhibitor. Suitable chaotropic salts include guanidinium
salts such as guanidine isothiocyanate, guanidine thiocyanate,
guanidine hydrochloride, sodium iodide, sodium perchlorate,
potassium iodide, sodium isothiocyanate, urea, or combinations
thereof.
The second stabilizing method also uses a dry solid storage medium
but a different adsorbed or absorbed stabilizer. Here, the
protectant composition comprises a protein denaturing agent (such
as an anionic detergent) and a free radical trap (such as a weak
base, and a chelating agent, and optionally, uric acid or a urate
salt).
BRIEF SUMMARY OF THE INVENTION
The present invention relates to a controlled transfer biological
collection device using a dry solid storage and transfer medium and
a method for the collection of biological material of interest
(genetic or proteinaceous material) in a form suitable for storage
and/or subsequent analysis.
The present collection device for a biological sample that contains
degradable biologically sourced analytes comprises three elements.
A moveable sample collection member is one element and is equipped
with an analyte collection surface that, preferably, has the
ability to absorb more sample than is necessary for transfer to a
storage medium. A storage medium suitable for collecting and
storing the biological sample is held in place by a storage medium
holder. The holder not only keeps the operator's fingers away from
the storage transfer location, but also provides a holding means
for holding the storage medium in a fixed position and for applying
contact pressure between the storage medium and the analyte
collection surface. The holder also has a means for holding the
moveable sample collection member. Thus, the two elements, the
storage medium and the analyte collection surface are held together
for traceability purposes.
Functionally, the moveable sample collection holding means allows
the moveable collection member, and its analyte collection surface,
to move between a first open position for collecting the biological
sample on the analyte collection surface prior to sample collection
and a second closed position facing or contacting at least a
portion of the storage medium after collection and transfer of the
sample. For the purposes of the present invention, the term
"surface" refers to more than a two-dimensional space, including
volume as well. Thus, a "surface" can be the volume of a foam pad,
for example, and not just its contact surface area.
In use, one takes the above described device and contacts the
analyte collection surface with the biological sample. The moveable
collection member is moved towards the storage medium such that the
analyte collection surface and the storage medium are brought in
contact, allowing the transfer of the biological sample to the
storage medium. In preferred embodiments, one engages the holding
means on the storage medium holder in doing so, thereby allowing
the analyte collection surface to be held facing the storage medium
after the transfer is complete.
Preferably, the means for holding the moveable sample collection
member comprises a resilient member, which may be molded into the
storage medium holder. In one embodiment, the resilient member is
such that, in use, it engages the moveable collection member and
releasably holds it in a fixed position such that the surface of
the moveable collection member is in contact with the storage
medium, thereby maintaining a uniform and constant pressure between
the moveable collection member surface and the storage medium.
Preferably the pressure is sufficient to facilitate the transfer of
the biological sample from the analyte collection surface of the
moveable sample collection member to the storage medium. The person
skilled in the art will be able to determine the relative position
of the resilient member which is required in order to ensure
sufficient transfer of the biological sample from the analyte
collection surface of the moveable sample collection member to the
storage medium.
For analysis of the biological sample, the storage medium is
manipulated so as to remove at least a portion of the biologically
sourced analyte present on the storage medium.
Examples of storage media suitable for the present invention
include untreated filter paper, such as #903.RTM. brand paper
(Whatman, Inc., Florham Park, N.J. USA) or treated filter papers,
such as FTA and FTA Elute brand paper (also from Whatman, Inc.,
Florham Park, New Jersey USA). These treated matrices are described
in US patents referenced above. Such treated matrices provide a
simple safe method for collection, shipping and storage of
biological samples. They also contain chemistries which make it
easy to isolate DNA from complex samples such as blood. Samples
collected on treated or untreated matrices are dried for storage
and can be stored at room temperature for long periods of time.
An object of the invention is to provide a controlled transfer of a
biological sample to a dry, treated solid storage and transfer
medium, such as providing a reproducible pressure or movement
between the analyte collection surface and the storage medium.
A second object of the invention is to provide a device or method
that has a spare sample source in sample retained in an absorbent
analyte collection surface.
A third object of the invention is to provide a device or method
that retains the sample collector surface and the storage medium
together for chain of custody traceability purposes.
A fourth object of the invention is to provide a device or method
in which the storage medium can be processed by automated analyzing
methods.
A fifth object of the invention is to provide a device or method
for the long term storage for biological samples.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a perspective view of a preferred embodiment of the
present invention showing the claimed element in a closed
position;
FIG. 2 is a perspective view of a preferred embodiment of the
present invention showing the claimed element in an open
position;
FIG. 3 is a plan and sectional view of the FIG. 1 device;
FIG. 4 is a plan and sectional view of the FIG. 2 device;
FIG. 5 is a perspective view of a further embodiment of the present
invention showing the claimed element in an open position;
FIG. 6 is a perspective view of a further embodiment of the present
invention showing the claimed element in a closed position;
FIG. 7 is a graph illustrating the PCR product concentrations
obtained from .beta.-globin PCR amplifications following use of
THP-1 cells in a device of the present invention;
FIG. 8a is a punch map showing the buccal cell application area
after transfer of buccal cells using a device according to the
present invention;
FIG. 8b illustrates the distribution of buccal cells on the storage
medium using the method of the present invention;
FIG. 8c is a box and whisker plot of PCR product concentrations
obtained after .beta.-globin PCR amplifications from 11 discs
punched from each FTA storage medium;
FIG. 9a is a comparison of the transfer patterns obtained using the
method of the present invention and the traditional swab
method;
FIG. 9b is a comparison between the method of the present invention
and swab methods for the collection of buccal cells from five
different donors; and
FIG. 10 shows the results of an STR analysis of four donor
individuals using Promega PowerPlex 16.
DETAILED DESCRIPTION OF THE INVENTION
A preferred embodiment is shown in FIG. 1. The collection device
(10) for a biological sample that contains degradable biologically
sourced analytes comprises a moveable sample collection member (20)
having an analyte collection surface (22), a storage medium (30),
and a storage medium holder (40) having a means for holding the
storage medium in a fixed position (50) and a means for holding the
moveable sample collection member (60). The moveable sample
collection holding means allows the moveable collection member
surface to move either from a first closed position facing or
contacting at least a portion of the storage medium (as shown in
FIGS. 1 and 3) to a second open position for collecting the
biological sample on the analyte collection surface (as shown in
FIGS. 2 and 4) or vice versa.
Preferably, the means for holding the moveable sample collection
member comprises a unitary connection between the storage medium
holder and the moveable sample collection member (as shown in the
FIGURES). Also preferably, the moveable sample collection surface
is dimensioned and configured to be in spring tension away from the
storage medium surface when held by the member holding means such
that the analyte collection surface is held off the storage medium
thereby allowing enough space for air drying of the storage medium
after transfer of the sample to the storage medium from that
surface.
Preferably the storage medium will also comprise at least one
stabilizing reagent that preserves at least one biological sample
analyte for transport or storage. Suitable such reagents include
either the combination of a weak base, a chelating agent, and,
optionally, uric acid or a urate salt or simply the addition of a
chaotropic salt, alone or in combination with a surfactant.
The "weak base" of the composition may be a Lewis base which has a
pH of about 6 to 10, preferably about pH 8 to 9.5. One function of
the weak base is to act as a buffer to maintain a composition pH of
about 6 to 10, preferably about pH 8.0 to 9.5, for example, pH 8.6.
Hence, a weak base suitable for the composition of the invention
may, in conjunction with other components of the composition,
provide a composition pH of 6 to 10, preferably, about pH 8.0 to
9.5. Suitable weak bases according to the invention include organic
and inorganic bases. Suitable inorganic weak bases include, for
example, an alkali metal carbonate, bicarbonate, phosphate or
borate (e.g., sodium, lithium, or potassium carbonate). Suitable
organic weak bases include, for example, tris-hydroxymethyl amino
methane (Tris), ethanolamine, triethanolamine and glycine and
alkaline salts of organic acids (e.g., trisodium citrate). A
preferred organic weak base is a weak monovalent organic base, for
example, Tris. The Tris may be either a free base or a salt, for
example, a carbonate salt.
A preferred chelating agent is a strong chelating agent. By
"strong" chelating agent it is meant that the agent binds
multivalent metal ions with a comparable or better affinity than
ethylene diamine tetraacetic acid (EDTA). A preferred chelating
agent according to the invention is EDTA.
Anioinic surfactants are examples of surfactants which are useful
in the present invention. A preferred anionic detergent is a strong
anionic detergent. As used herein, a "strong" anionic detergent
includes a hydrocarbon moiety, aliphatic or aromatic, containing
one or more anionic groups. Particularly preferred anionic
detergents suitable for the invention include sodium dodecyl
sulphate (SDS) and sodium lauryl sarcosinate (SLS). In a preferred
embodiment, the anionic detergent causes inactivation of most
microorganisms which have protein or lipids in their outer
membranes or capsids, for example, fungi, bacteria or viruses. This
includes microorganisms which may be pathogenic to humans and are
present in a biological sample.
Also preferably, the storage medium will have a visual delineation
(32) placed around the transfer area of the storage medium such
that if removed from the storage holding means an operator can know
where the material was deposited without reference to the
device.
The present device can be used to collect degradable biologically
sourced analytes such as nucleic acids, proteins, and respective
fragments thereof. The biological sample can be selected from the
group consisting of saliva, blood, serum, lymph fluids, buccal
cells, mucosal cells, cerebrospinal fluid, semen, vaginal fluid,
feces, plasma, urine, a suspension of cells, or a suspension of
cells and viruses.
Preferably, the present device is dimensioned and configured such
that the storage medium holder (40) releaseably holds the storage
medium (30) in the fixed position by the holding means (50) (such
as the plastic arms shown in the FIGURES). Thus, one can separate
the storage medium from the storage holder for subsequent
processing or storage. The tension on the storage medium should
allow for manual or automated extraction, but not allow for
accidental loss of the storage medium from the device.
As described above, the means for holding the moveable sample
collection member may comprise a resilient member (70) positioned
on the storage medium holder. This is illustrated in FIG. 5. In
use, where the moveable sample collection member is moved to a
closed position, the resilient member on the storage medium holder
engages the moveable collection member and releasably holds it in a
fixed position such that the surface thereof is in contact with the
storage medium, thereby maintaining a uniform and constant pressure
between the moveable collection member surface and the storage
medium.
In some cases, one can dimension and configure the storage medium
holder so as to expose at least a portion of the storage medium for
removal of the storage medium from the storage medium holder.
Preferably, the analyte collection surface (22) comprises an
absorbent material, such as a conventional porous polyurethane foam
pad (from Powell Products, Inc. of Colorado Springs, Colo. USA),
that is suitable for collecting a biological sample. Examples of
other suitable absorbent materials include hydrophilic
non-reticulated, closed cell foams, hydrophilic, non-reticulated,
open cell foams, hydrophobic non-reticulated closed cell foams,
hydrophobic non-reticulated open cell foams, hydrophobic
reticulated open cell foams, absorbent gel materials used for
transfers and cotton based absorbent material. The analyte
collection surface should be dimensioned and configured such that
the volume of sample is controlled. By controlling the volume, any
stabilizing reagents on the storage medium are not overloaded in
their respective protecting capacity. If used in buccal swab
applications, the pad should be dimensioned and configured to fit
within the human mouth.
For record keeping and traceability the present device should also
comprise an identification label (such as conventional bar coding)
on not only the storage medium, but also the collection member, and
if not unitary, the storage medium holder as well.
To ensure device integrity, the present device can also comprise a
sterility envelope surrounding the other device elements.
Preferably, those other elements are sterile and free from any
biological sample analytes (made for example, from medical grade
plastics), which can be done through conventional techniques such
as irradiation after the envelope is sealed.
Kits can be made that incorporate the above device along with any
combination of associated equipment or reagents including
purification reagents, buffers, or the like and storage systems,
containers, or the like.
In this regard, the present invention further provides a kit
comprising a device as defined herein and one or more components
selected from the group consisting of purification reagents for
subsequent analysis of the sample, buffers, storage systems and
containers.
Example of Device Use
The present device can be used for biological sample collection for
the following purposes: the collection of buccal cell samples for
criminal databases; the collection of crime scene samples (i.e.,
rehydrated blood, semen, saliva and liquid samples of the same);
the collection of sexual assault samples; the collection of buccal
samples for population genetics or pharmacogenomics studies; the
collection of buccal samples for personal genetic ID archiving; the
collection of bacterial or parasite samples from food sources; the
collection of blood from meat at slaughterhouse for meat
traceability; or the collection of biological samples from animals
for veterinary diagnostics.
EXAMPLES
Example 1
Cell Transfer Assays
Cell transfer assays were performed in order to evaluate the
transfer efficiency of the device of the present invention. The
device used in each of these experiments was a device as
illustrated in FIG. 5. The analyte collection surface was formed
from foam (Aquazone.RTM. available from Reilly Foam Corporation,
PA, USA) and the storage medium comprised FTA filter paper
(obtained from Whatman, Inc., New Jersey, USA).
THP-1 cultures were grown to densities of 10.sup.6 cells/ml,
centrifuged and subsequently resuspended at a concentration of
10.sup.7 cells/ml. A serial dilution of this stock was performed to
give concentrations of 10.sup.5, 10.sup.4 and 10.sup.3 cells/ml.
Each of these dilutions was applied to the foam collection surface
of a device according to the present invention (100 .mu.l each);
the devices were then closed and clipped in place for 10 seconds
before release of the applicator foam to the resting position.
2 mm discs were punched from the white application area of the pink
indicator FTA filter paper card and placed into 0.5 ml tubes with
200 .mu.l FTA Purification Reagent. Following a five minute
incubation at room temperature, the tubes were finger-flicked for
10 seconds. Liquid was removed and the wash step repeated two more
times for a total of three washes with FTA Purification Reagent. TE
buffer (200 .mu.l) was added to each tube, incubated for 5 minutes
at room temperature, and the TE was removed and discarded. This was
repeated for a total of two washes using TE buffer, after which the
disc was dried for 1 hour at room temperature.
PCR amplification of the .beta.-globin gene and capillary
electrophoresis were then performed. Analysis was performed using
.beta.-globin PCR assays via Exeprion Bioanalyzer 1K DNA chips. DNA
detection was defined as the presence of .beta.-globin amplicons on
the Experion 1K Chips with a detection limit at 0.1 ng/.mu.l.
The results obtained are set out in FIG. 7 which illustrates that
detectable amplification was observed using all concentrations of
cells. More specifically, PCR product was successfully detected
even following application of only 100 cells to each device.
Excellent results were obtained where 1000 cells were applied to
the applicator foam to yield .beta.-globin PCR amplicon
concentrations ranging from 1.5 to 3.2 ng/.mu.l.
Example 2
Buccal Cell Mapping Experiments
Samples were collected from four subjects, each using two devices
as illustrated in FIG. 5. The samples were collected according to
the following protocol: a) Holding the plastic stem above the hinge
joint, the foam tip of the device was placed in the mouth of the
subject and the foam analyte collection surface was rubbed on the
inside of the cheek for 15 seconds. This procedure was repeated
using the opposite cheek. The foam analyte surface was rubbed along
the gum-line, at the fold line of the cheek and under the tongue,
soaking up as much saliva as possible. The foam analyte surface was
then removed from the mouth. b) The protective film of the storage
medium was removed, exposing the FTA Card storage medium. c) The
device was folded at the hinge joint and the foam analyte surface
was pressed onto the FTA Card making sure that the foam sample
collection surface was held in place by the clip at the front of
the FTA Card holder. The device was then closed and the sample
collection member was pushed into the lowest position on the clip.
The device was left in this position for 10 seconds. d) Whilst
holding the FTA Card holder, the device handle was bent back to
release the foam sample collection surface from the clip and to
pull the sample collection member up to the top position on the
clip. The device was bent to lift the foam sample collection
surface from the FTA Card storage medium. e) The FTA card storage
medium was removed and dried for 3 hours, ready for subsequent
analysis.
Eleven discs (2.0 mm diameter) were punched from each card as shown
in FIG. 8a, and PCR amplifications targeting a 268 by portion of
the .beta.-globin gene were completed and are shown in FIG. 8b. The
amplicons were quantified using an Experion analyzer (Bio-Rad) and
are shown graphically in FIG. 8c as a Box and Whiskers Plot. A
total of 88 punches were analyzed from eight Indicating FTA cards;
87 contained sufficient DNA template for successful PCR, i.e. only
1 failure in 88 punches (in this case, the failed punch was taken
from the periphery of the application area). Negative controls
included paper-only samples (devoid of biological sample) and water
only (no template PCR). In both negative control cases,
amplification of PCR products was not detected.
With reference to FIG. 8a, the punch maps show the buccal cell
application area after transfer of buccal cells from the foam
applicator to the Indicating FTA card (storage medium) using the
device of the present invention. Eleven 2 mm punches were removed
from each card as shown in FIG. 8a. The large circle represents the
typical area of cell transfer indicated by a change in Indicating
FTA color from pink to white.
With reference to FIG. 8b, the concentration of DNA detected is
directly proportional to the number of buccal cells transferred to
the FTA card. Four different donors used device of the present
invention to harvest buccal cells from inside their cheeks and
transfer them to Indicating FTA cards for analysis. Panels A-D show
DNA distribution maps of DNA on the FTA card after transfer of
cells from the devices. Each data point represents the yield of PCR
amplicons (ngs) produced from the .beta.-globin amplification of
DNA present on a 2 mm disk. The PCR amplification was quantified
using the Experion Bioanalyzer. The distribution of DNA present on
the cards indicates that the transfer of cells was consistently
uniform.
With reference to FIG. 8c, the range is shown as the whiskers and
the box shows the area where 50% of the data points lie. The bar in
the box represents the median value for the 11 data points. The
data shown in the Box and Whiskers Plot indicates that the transfer
of buccal cells from the sample collection surface to the storage
medium was consistent. Sample 1B contains a single failed PCR
reaction; the only one out of 88 PCR amplifications. Sample 2A
contained a single outlier point that skewed the upper range of PCR
yields, and this is likely the result of a cell-clump transferred
to the FTA card. PCR products showed minor variation in
concentration within an individual set, but the variation is most
notable between subjects; for example subject #4 harvested
substantially more cells than other subjects on both collection
devices used. This serves to underscore the differences in shedding
buccal cells from one person to the next.
The final set of experiments utilizing buccal cell maps are
displayed in FIGS. 9a and 9b, respectively. These figures show the
results of a comparative analysis of the method of the present
invention against the traditional swab method of buccal cell
collection. Five buccal cell donors collected two buccal cell FTA
cards using the method described above and two cards using the
traditional swab method. The protocol for cell collection
identified above was followed except that the swab was rolled onto
the FTA card (storage medium).
Each donor was sampled a total of four times (A-D), using two
devices of the invention and two swabs. To remove sampling order
bias, the collection method order was varied between individuals in
the order shown in FIG. 9b (A=1.sup.st to D=4.sup.th). Following
sample collection, FTA cards were processed using standard
protocols as described above and PCR was performed to amplify a
fragment of the .beta.-globin gene from 11 positions within the
application area as described above. Resultant PCR products were
quantified using an Experion Bioanalyzer.
The comparison of performance between the device of the present
invention and the traditional swab method reveals that the present
method provides for a well defined area of buccal cell transfer
while the swab produces variable transfer patterns that require the
user to make a "best guess" of where to collect a punch sample
(FIG. 9a). The device of the present invention provides a well
defined application area making automated punching more accurate.
The Box and Whiskers Plot in FIG. 9b shows that the method using
the device of the present invention consistently collects higher
yields of buccal cells and generates a more uniform transfer of
cells than does the swab method regardless of the order in which
samples were collected.
Example 3
STR Analysis
Buccal samples utilized for STR analysis were taken from the same
collection devices in Example 2 above. Two 1.2 mm punches were
collected from central locations of each Indicating FTA card
storage medium. All punches were washed and dried following the
protocol outlined in Example 1.
STR analysis was performed using the Promega PowerPlex 16.RTM.
system following the manufacturer's instructions. A processed and
dried Indicating FTA punch was used in each PCR reaction as a
method of direct amplification from the punch. PCR was carried out
on an Applied Biosystems 7900HT, and PCR products were visualized
on an Applied Biosystems 310 Genetic Analyzer. Analysis of products
was carried out with GeneMapper 3.2.RTM. software.
All 4 sets of buccal collection produced excellent quality results
for all 16 alleles above 250 RFU's (relative fluorescent units) as
seen in FIG. 10. This exceeds the desired criterion from the Design
Input document of 200 RFU's. Although, there was some minor
variation in the intensity of the peaks, the peak balance and peak
intensity remained well within the GeneMapper software acceptable
parameters. As expected, replicate devices from the same individual
produced the same allelic profile. Allelic profiles are found in
Table I. A series of 50 samples were collected with the device of
the present invention, processed and analyzed using Promega's
PowerPlex 16 system of STR analysis (Table 2).
TABLE-US-00001 TABLE 1 D3S1358 TH01 D21S11 D18S51 Penta_E D5S818
D13S317 D7S820 Donor 1 17 6/9.3 28/29 13/15 12/14 8/11 12 10/11
Donor 2 14/16 7/8 30/31 17 7/12 10/11 8/12 10/11 Donor 3 16/17 9.3
30/31 12/16 5/13 11/12 11 11/12 Donor 4 15/17 9/9.3 29/30 15/20
7/15 11/13 11/12 8/12 D16S539 CSF1PO Penta_D AMEL vWA D8S1179 TPOX
FGA Donor 1 11/13 10/12 10/13 X/Y 18 13 9/11 22/22.3 Donor 2 9/13
12/13 10/13 X/Y 17/18 14/17 8/11 20/24 Donor 3 11/14 11/12 9 X
15/17 14 8/11 21/23 Donor 4 11/13 10/12 9/13 X 16/17 11/14 8
19/21
TABLE-US-00002 TABLE 2 number of CODIS Penta Promega's PowerPlex 16
STR System samples Amelogenin alleles D & E Totals Total
possible allele calls 50 50 650 100 800 Total correct allele calls*
49 49 642 98 789 Total failed allele calls 1 1 8 2 11 Re-run of
failed sample correct allele 1 1 13 2 16 calls** Total Correct
Allele calls after sample 50 50 650 100 800 re-run % accuracy after
first set of injections 98.6% % accuracy after failed sample re-run
100% *all allele calls of peaks with .gtoreq.200 RFU **10 second
reinjection of sample; peak balance was <60% for several
heterozygous peaks
In FIGS. 10, A, B, C, and D are results from buccal cell donors 1,
2, 3, and 4 respectively. The red line indicates the point of 250
rfu's. Both Penta D and E alleles are marked as indicators for DNA
template quality since they are typically the first alleles to fail
when it is compromised resulting in allele drop-out. In the
electropherograms below, the template quality is excellent with
peak balance running 85% to 100%, well above the acceptable range
of 60% for accurate allele calls.
* * * * *